In the Research Article by Alvena K Kureshi, Rosemary AL Drake and Julie T Daniels, ‘Challenges in the development of a reference standard and potency assay for the clinical production of RAFT tissue equivalents for the cornea’, which appeared in the March 2014 issue of Regenerative Medicine (Regen. Med. 9[2], 167–177 [2014]), the Directive number mentioned in the following sentence (page 167) is incorrect and was published as follows:
“Since poorly controlled manufacture and inadequate characterization may affect product safety and efficacy, the ATMP Tissue and Cells Directive (2004/23/EC) describes the use of Reference Standards and Potency Assays, a well-established system in the mature pharmaceutical manufacturing industry.”
The correct Directive number is:
“Since poorly controlled manufacture and inadequate characterization may affect product safety and efficacy, the ATMP Tissue and Cells Directive (2009/120/EC) describes the use of Reference Standards and Potency Assays, a well-established system in the mature pharmaceutical manufacturing industry.”
The authors would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.